CTOR logo

CTOR
Citius Oncology Inc.

1,354
Mkt Cap
$73.27M
Volume
25,868.00
52W High
$6.19
52W Low
$0.4912
PE Ratio
-2.69
CTOR Fundamentals
Price
$0.793
Prev Close
$0.83
Open
$0.80
50D MA
$0.9012
Beta
-2.23
Avg. Volume
435,238.11
EPS (Annual)
-$0.338
P/B
1.20
$148.61
Loading...
Loading...
News
all
press releases
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...
PR Newswire·16d ago
News Placeholder
More News
News Placeholder
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire·23d ago
News Placeholder
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened
Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.8% - Time to Sell...
MarketBeat·23d ago
News Placeholder
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·1mo ago
News Placeholder
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update
Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates
Citius Oncology (NASDAQ:CTOR - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of...
MarketBeat·2mo ago
News Placeholder
Citius Oncology Q1 Earnings Summary & Key Takeaways
read more...
Benzinga·2mo ago
News Placeholder
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·2mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
PR Newswire·2mo ago
<
1
2
...
>

Latest CTOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.